Cargando…
Anti-Endothelial Cell Antibodies are not frequently elevated in hospitalized patients with COVID-19
COVID-19 is now established to be associated with a thrombotic phenomenon, now called COVID-19 associated coagulopathy (CAC). Anti-Endothelial Cell Antibodies (AECA) are a heterogenous group of autoantibodies targeting various endothelial cell antigens or antigens adhering to endothelial cells. Thes...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mattioli 1885
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171859/ https://www.ncbi.nlm.nih.gov/pubmed/35546028 http://dx.doi.org/10.23750/abm.v93i2.11196 |
_version_ | 1784721761804222464 |
---|---|
author | Michael Henry, Brandon Benoit, Stefanie W. Vikse, Jens Favaloro, Emmanuel Benoit, Justin L. Lippi, Giuseppe |
author_facet | Michael Henry, Brandon Benoit, Stefanie W. Vikse, Jens Favaloro, Emmanuel Benoit, Justin L. Lippi, Giuseppe |
author_sort | Michael Henry, Brandon |
collection | PubMed |
description | COVID-19 is now established to be associated with a thrombotic phenomenon, now called COVID-19 associated coagulopathy (CAC). Anti-Endothelial Cell Antibodies (AECA) are a heterogenous group of autoantibodies targeting various endothelial cell antigens or antigens adhering to endothelial cells. These antibodies are commonly observed in a variety of auto-immune and rheumatologic conditions, and were observed in patients with the severe acute respiratory syndrome (SARS) in 2005. We aimed to assess AECA status in patients with COVID-19 and their potential contributing role to endothelial injury and CAC. AECA identification was a relatively infrequent finding in COVID-19 patients on admission, and their presence, albeit in only 2/33 patients, was not associated with disease severity. However, as the autoantibodies were only measured at admission, we cannot exclude the possibility of pathogenic AECA developing later in the course of disease. Further studies using additional methods are needed to evaluate the presence and potential pathogenic role of AECA in later stages of COVID-19. (www.actabiomedica.it) |
format | Online Article Text |
id | pubmed-9171859 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Mattioli 1885 |
record_format | MEDLINE/PubMed |
spelling | pubmed-91718592022-06-29 Anti-Endothelial Cell Antibodies are not frequently elevated in hospitalized patients with COVID-19 Michael Henry, Brandon Benoit, Stefanie W. Vikse, Jens Favaloro, Emmanuel Benoit, Justin L. Lippi, Giuseppe Acta Biomed Reviews/Focus on COVID-19 is now established to be associated with a thrombotic phenomenon, now called COVID-19 associated coagulopathy (CAC). Anti-Endothelial Cell Antibodies (AECA) are a heterogenous group of autoantibodies targeting various endothelial cell antigens or antigens adhering to endothelial cells. These antibodies are commonly observed in a variety of auto-immune and rheumatologic conditions, and were observed in patients with the severe acute respiratory syndrome (SARS) in 2005. We aimed to assess AECA status in patients with COVID-19 and their potential contributing role to endothelial injury and CAC. AECA identification was a relatively infrequent finding in COVID-19 patients on admission, and their presence, albeit in only 2/33 patients, was not associated with disease severity. However, as the autoantibodies were only measured at admission, we cannot exclude the possibility of pathogenic AECA developing later in the course of disease. Further studies using additional methods are needed to evaluate the presence and potential pathogenic role of AECA in later stages of COVID-19. (www.actabiomedica.it) Mattioli 1885 2022 2022-05-11 /pmc/articles/PMC9171859/ /pubmed/35546028 http://dx.doi.org/10.23750/abm.v93i2.11196 Text en Copyright: © 2022 ACTA BIO MEDICA SOCIETY OF MEDICINE AND NATURAL SCIENCES OF PARMA https://creativecommons.org/licenses/by-nc-sa/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License |
spellingShingle | Reviews/Focus on Michael Henry, Brandon Benoit, Stefanie W. Vikse, Jens Favaloro, Emmanuel Benoit, Justin L. Lippi, Giuseppe Anti-Endothelial Cell Antibodies are not frequently elevated in hospitalized patients with COVID-19 |
title | Anti-Endothelial Cell Antibodies are not frequently elevated in hospitalized patients with COVID-19 |
title_full | Anti-Endothelial Cell Antibodies are not frequently elevated in hospitalized patients with COVID-19 |
title_fullStr | Anti-Endothelial Cell Antibodies are not frequently elevated in hospitalized patients with COVID-19 |
title_full_unstemmed | Anti-Endothelial Cell Antibodies are not frequently elevated in hospitalized patients with COVID-19 |
title_short | Anti-Endothelial Cell Antibodies are not frequently elevated in hospitalized patients with COVID-19 |
title_sort | anti-endothelial cell antibodies are not frequently elevated in hospitalized patients with covid-19 |
topic | Reviews/Focus on |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171859/ https://www.ncbi.nlm.nih.gov/pubmed/35546028 http://dx.doi.org/10.23750/abm.v93i2.11196 |
work_keys_str_mv | AT michaelhenrybrandon antiendothelialcellantibodiesarenotfrequentlyelevatedinhospitalizedpatientswithcovid19 AT benoitstefaniew antiendothelialcellantibodiesarenotfrequentlyelevatedinhospitalizedpatientswithcovid19 AT viksejens antiendothelialcellantibodiesarenotfrequentlyelevatedinhospitalizedpatientswithcovid19 AT favaloroemmanuel antiendothelialcellantibodiesarenotfrequentlyelevatedinhospitalizedpatientswithcovid19 AT benoitjustinl antiendothelialcellantibodiesarenotfrequentlyelevatedinhospitalizedpatientswithcovid19 AT lippigiuseppe antiendothelialcellantibodiesarenotfrequentlyelevatedinhospitalizedpatientswithcovid19 |